z-logo
Premium
Intravenous digoxin as a bioavailability standard: Slow infusion and rapid injection
Author(s) -
Greenblatt David J.,
Duhme David W.,
KochWeser Jan,
Smith Thomas W.
Publication year - 1974
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1974155510
Subject(s) - digoxin , bioavailability , radioimmunoassay , excretion , medicine , crossover study , urinary system , pharmacokinetics , pharmacology , anesthesia , heart failure , alternative medicine , pathology , placebo
Eight healthy male subjects received intravenous digoxin (0.75 mg) by rapid infection and by 1 hour infusion in a single‐dose crossover study. Multiple serum concentrations and 6 day urinary excretion of digoxin were determined by radioimmunoassay. Mean 6 day cumulative urinary excretion of digoxin after infusion (0.57 mg) was significantly greater than after rapid injection (0.52 mg). Between‐subject variability in urinary excretion after infusion was significantly less than that after rapid injection. Thus, administration of digoxin by slow infusion is preferable as an intravenous standard in bioavailability testing.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom